Patent ID: 8778339
Filing Date: 2014-07-15
Classification: A61K,A61P,C07K,G01N

Abstract:
1. A pharmaceutical composition comprising: (A) an effective amount of a first isolated antibody or an antigen-binding fragment thereof that comprises a variable domain that specifically binds the extracellular domain of native human FcγRIIB with greater affinity than said antibody or fragment thereof binds native human FcγRIIA, wherein said first isolated antibody comprises: (B) an effective amount of a second isolated antibody or an antigen-binding fragment thereof that comprises a variable domain that comprises three light chain CDRs and three heavy chain CDRs, wherein said variable domain specifically binds human CD20; and (C) a pharmaceutically acceptable carrier; wherein said effective amounts of said first and second antibodies or said fragments thereof cause said pharmaceutical composition to mediate a synergistically increased tumor volume reduction relative to the additive tumor volume reductions mediated by: